AbbVie Inc. (NYSE:ABBV) has declared another quarterly dividend of $1.73 per share. The dividend will be paid on November 16, ...

AbbVie Inc. ABBV shares are edging higher Friday morning following Thursday’s announcement of positive Phase 3 trial results ...

Wolfe Research upgraded two prominent pharmaceutical companies to Outperform on August 13. The firm upgraded both Biogen Inc.

AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

AbbVie Inc. (ABBV), the North Chicago, Illinois-based Pharma giant, is expected to report its Q1 2026 earnings around April 29th - in just under three weeks' time. A few days ago, AbbVie released an 8 ...

AbbVie presented new VRAYLAR (cariprazine) data at Psych Congress 2026 in New Orleans, including results from two prospective real-world observational studies in major depressive disorder (MDD) and ...

Key Points Interested in AbbVie Inc.? Here are five stocks we like better. SKYRIZI and RINVOQ remain AbbVie’s main growth ...

AbbVie Inc. stock stands at USD 257.17 on the NYSE as of September 11, 2026, close to its 52-week high of USD 267.47.

AbbVie Inc. ( ABBV) on Friday announced that it presented new real-world data on VRAYLAR at Psych Congress 2026 in New Orleans, highlighting its use in adults with major depressive disorder and ...

AbbVie Inc. (NYSE:ABBV) said its migraine treatment atogepant, sold as Qulipta in the U.S., met the main goal of a late-stage ...

In a press release sent earlier today, the Waltham, Massachusetts based biotech company Apogee Therapeutics, Inc. (APGE) announced its proposed acquisition by the Illinois based Pharma giant AbbVie ...

Final results from a long-term, open-label study evaluating the safety and tolerability of VRAYLAR among pediatric patients with BP-I disorder, schizophrenia or autism spectrum disorder, which showed ...